Skip to main content
. 2019 Mar 13;155(5):625–627. doi: 10.1001/jamadermatol.2018.5595

Table 1. Incidence of Poor Outcomes in Immunosuppressed and Immunocompetent Patients Stratified by Number of Squamous Cell Carcinoma (SCC) Tumorsa.

SCCs, No. Patients, No. (%) LR NM ITM Any PO
No. (%) P Value No. (%) P Value No. (%) P Value No. (%) P Value
Immunosuppressed cases
1 46 (43.4) 2 (4.3) 1 [Reference] 2 (4.3) 1 [Reference] 2 (4.3) 1 [Reference] 4 (8.7) 1 [Reference]
2-9 47 (44.3) 14 (29.8) .001 3 (6.4) >.99 3 (6.4) >.99 15 (31.9) <.001
≥10 13 (12.3) 9 (69.2) <.001 1 (7.7) .53 0 >.99 9 (69.2) <.001
Immunocompetent controls
1 159 (75.0) 13 (8.2) 1 [Reference] 1 (0.6) 1 [Reference] 2 (1.3) 1 [Reference] 13 (8.2) 1 [Reference]
2-9 53 (25.0) 2 (4.0) .37 0 >.99 0 >.99 2 (4.0) .37
≥10 0 NA NA NA NA NA NA NA NA

Abbreviations: ITM, in-transit metastases; LR, local recurrence; NA, not applicable; NM, nodal metastases; PO, poor outcomes.

a

Fisher exact statistics were used when cell sample size was fewer than 5.